title: Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid.
authors.affiliation: From the Departments of Surgery (E.E.M., H.B.M., E.G., M.P.C., K.C.H., A.S., A.B.) and Pediatrics (C.C.S.), University of Colorado Denver, Aurora; Department of Surgery (E.E.M., H.B.M., E.G., M.P.C., A.S.), Denver Health Medical Center; and Bonfils Blood Center (C.C.S.), Denver, Colorado.
authors.forename: Ernest E
authors.initials: EE
authors.lastname: Moore
authors.forename: Hunter B
authors.initials: HB
authors.lastname: Moore
authors.forename: Eduardo
authors.initials: E
authors.lastname: Gonzalez
authors.forename: Michael P
authors.initials: MP
authors.lastname: Chapman
authors.forename: Kirk C
authors.initials: KC
authors.lastname: Hansen
authors.forename: Angela
authors.initials: A
authors.lastname: Sauaia
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Silliman
authors.forename: Anirban
authors.initials: A
authors.lastname: Banerjee
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016913:Blood Component Transfusion; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D014148:Tranexamic Acid / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000503:physiopathology*
chemical_list: D000933:Antifibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; D014148:Tranexamic Acid; D005341:Fibrinolysin